A rapid and specific semi‐micro method involving high‐pressure liquid chromatography for the assay of metronidazole in plasma, saliva, serum, urine and whole blood.

Kaye, C M; Sankey, M. G.; Thomas, L A

doi:10.1111/j.1365-2125.1980.tb05856.x

Cited by 43 publications

(13 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the time of milk sampling the infants were test weighed and 1 to 2 hours later they had a blood sample taken as peak plasma concentrations occur within 30 minutes to 3 hours after oral administration [4]. The analyses for metronidazole and its hydroxy metabolite (I) in milk and plasma were performed as a specific semi-micro high-pressure liquid Chromatographie method as described by K.AYE and co-workers [10]. The limit of sensitivity was less than 0.1…”

Section: Methodsmentioning

confidence: 99%

Blood and milk concentrations of metronidazole in mothers and infants

Heisterberg¹,

Branebjerg²

1983

Journal of Perinatal Medicine

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Blood and milk concentrations of metronidazole in mothers and infants

Heisterberg¹,

Branebjerg²

1983

Journal of Perinatal Medicine

View full text Add to dashboard Cite

“…After centrifugation, samples of serum and SF were stored at -70°C until assayed. A specific high pressure liquid chromatographic method was used as previously described (Kaye et al, 1980) to measure the level of metronidazole and its oxidative metabolite, 20396 RP [1 -(2 -hydroxyethyl) -2 -methyl -5 -nitroimidazole), which also has some anti-anaerobic activity. Fig.…”

Section: Methodsmentioning

confidence: 99%

“…Although the pharmacokinetic aspects of metronidazole have been studied intensively, using plasma or serum (Houghton et al, 1979a, b;Bergan and Arnold, 1980;Amon et al, 1981), and it has been shown that the drug is present in cerebrospinal fluid (Barling and Selkon, 1978) and saliva (Kaye, Sankey and Thomas, 1980), nothing is known of the ability of this antibiotic to permeate the synovial fluid (SF). Therefore, it was considered pertinent to investigate the permeability of the synovial cavity to metronidazole, because of its relevance to the treatment of joint sepsis due to anaerobic organisms (Eykyn, 1979).…”

Section: Introductionmentioning

confidence: 99%

The penetration of metronidazole into synovial fluid

Sattar

Sankey

Cawley

et al. 1982

Postgraduate Medical Journal

View full text Add to dashboard Cite

SummarySix patients with non-infected synovial effusions, associated either with inflammatory or degenerative arthropathy and requiring diagnostic or therapeutic aspiration, were given a short course of 400mg metronidazole (Flagyl) 8-hourly for 3 doses. Serum and synovial fluid (SF) were sampled frequently during this time, and assayed for metronidazole by a specific high pressure liquid-chromatographic method. It was found that concentrations of metronidazole in SF reached those in serum after a short time-lag, and thereafter approximated to the serum concentration. With this regimen, metronidazole concentrations were readily achieved in synovial fluid, above the minimum inhibitory concentrations for most susceptible anaerobes. These results indicate that the drug freely enters the synovial fluid and suggests that metronidazole would prove effective in the treatment of septic arthritis due to anaerobic bacteria.

show abstract

“…The drug and its metabolites were analyzed employing a semimicro method in volving high-pressure liquid chromatography [ 15].…”

Section: Methodsmentioning

confidence: 99%

Systemic Concentrations of Metronidazole and Its Main Metabolites after Intravenous Oral and Vaginal Administration

Fredricsson¹,

Hagström

Nord

et al. 1987

Gynecol Obstet Invest

View full text Add to dashboard Cite

Metronidazole kinetics was studied in 5 healthy women after a single dose given intravenously, orally or vaginally, 500, 400 and 500 mg, respectively. Serum levels of the drug and of its hydroxy and acid metabolites were assessed. The results after intravenous and oral boluses were consistent with previous reports. After vaginal dose maximum serum levels of about 1 µg/ml of the drug were obtained between 9 and 24 h after the dose. Maximum concentration of the hydroxy metabolite was about 0.3 µg/ml after 24 h. Bioavailability of the drug was 19 ± 3 % after the vaginal dose as compared to 100 ± 5 % after the oral dose. Daily insertion into the vagina of 500 mg metronidazole resulted in a maximum serum concentration of 1.2 ± 0.2 µg/ml of the parent drug and of 0.6 ± 0.1 µg/ml of the hydroxy metabolite after about 3 days (range 2–4) after which no accumulation was noted. Urinary excretion of the metabolites was considerably lower after vaginal than after intravenous or oral administration, but the proportion between the two metabolites in the urine was constant.

show abstract

A rapid and specific semi‐micro method involving high‐pressure liquid chromatography for the assay of metronidazole in plasma, saliva, serum, urine and whole blood.

Cited by 43 publications

References 8 publications

Blood and milk concentrations of metronidazole in mothers and infants

Blood and milk concentrations of metronidazole in mothers and infants

The penetration of metronidazole into synovial fluid

Systemic Concentrations of Metronidazole and Its Main Metabolites after Intravenous Oral and Vaginal Administration

Contact Info

Product

Resources

About